课题基金 / 基金详情

A Preventative Adenoviral-Based H5N1 Influenza Vaccine

A Preventative Adenoviral-Based H5N1 Influenza Vaccine
基于腺病毒的预防性 H5N1 流感疫苗
批准号:
7077267
负责人:
ANDREA GAMBOTTO
金额:
$96.24万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-01 至 2008-07-31

项目摘要

项目成果

ANDREA GAMBOTTO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Wild waterfowl, the natural hosts of all known influenza A viruses, are the source of viruses which cause sporadic outbreaks of highly fatal disease in domestic poultry. Since 1997, highly pathogenic (HP) avian influenza A H5N1 viruses have caused a series of outbreaks in Hong Kong, and most recently in 9 other Asian countries. As human exposure to and infection with H5N1 viruses continues to increase, so too does the likelihood of the generation of an avian-human reassortant virus which may transmit efficiently within the human population which lacks HA-specific immunity to H5N1 viruses. In 1997, HPAl H5N1 in Hong Kong resulted in transmission from poultry to humans, resulting in 18 infected people and six deaths. In 2003- 2005, extensive outbreaks of highly pathogenic avian influenza A (H5N1) occurred in several Asian countries (Cambodia, China, Indonesia, Japan, Laos, South Korea, Thailand and Vietnam, North Korea), resulting in 17 human cases in Thailand and 27 in Vietnam and 3 in Cambodia; there were 51 reported deaths. H5N1 infections in family clusters have raised the possibility of human-to-human transmission of H5N1 virus. We have recently developed an adenoviral-based influenza vaccine encoding the hemagglutinin (HA) antigen of the A/Vietnam/1203/2004 (H5N1) strain isolated during the 2003-2005 lethal human outbreak. Vaccinated mice and chickens had broad virus-specific cellular and humoral immunity and were fully protected from a lethal intranasal H5N1 challenge, whereas all control animals died within few days. Hence, a centralized and integrated clinical vaccine testing will be proposed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
U01 Proposal Transfer - 2021
  • 批准号:
    10406767
  • 项目类别:
  • 资助金额:
    $325.08万
  • 财政年份:
    2019
  • 负责人:
    ANDREA GAMBOTTO
  • 依托单位:
Pre-clinical evaluation of a Zika virus vaccine
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
国内基金
海外基金
靶向Human ZAG蛋白的降糖小分子化合物筛选以及疗效观察
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    胡文静
  • 依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
自闭症相关基因CHD8在非人灵长类大脑发育中的作用
HBV S-Human ESPL1融合基因在慢性乙型肝炎发病进程中的分子机制研究
  • 批准号:
    81960115
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    34.0万元
  • 批准年份:
    2019
  • 负责人:
    江建宁
  • 依托单位: